Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 18, Issue 20, Pages 2883-2890Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212800672750
Keywords
Cancer; inflammation; kinase; P-TEFb; inhibitor; therapeutics; angiogenesis
Categories
Funding
- Ministry of Education, Youth and Sports of the Czech Republic [MSM6198959216]
- Czech Science Foundation [P305/12/0783]
- Medical Research Council Program grant [G0901526]
- MRC [G0901526] Funding Source: UKRI
- Medical Research Council [G0901526] Funding Source: researchfish
Ask authors/readers for more resources
Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available